BRAF and follicular variant thyroid gland papillary carcinoma: The markedly lower sensitivity of BRAF V600E testing for FVPTC (40.0%) compared to classical PTC (90.2%) in our cohort aligns with the established molecular pathogenesis of these subtypes.